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Accepted 7 September 2009AbstractObjective: Pain affects many cancer patients in advancing stages, lowering the level of their quality of life. Morphine has long been the “gold
standard” for the treatment of cancer pain; however, its side effects, particularly sedation and cognitive impairment at high doses, have encouraged
the use of “opioid rotation”. The transdermal fentanyl patch has advantages over oral morphine, with reduced side effects and increased conve-
nience in practical usage. The side effects were reduced in patients who changed to the fentanyl patch, but rescue analgesia was often needed
because of the decrease of fentanyl release from the patch, especially on patch replacement day. To maintain a stable fentanyl plasma level before
patch replacement, we have established a three-cycle fentanyl patch system and reported that it provided appropriate pain control. The objective of
this study was to investigate the individual variability of plasma fentanyl concentration in a three-cycle fentanyl patch system.
Case Report: The gynecologic cancer patients were treated using the three-cycle fentanyl patch system. Blood samples were taken from the
patients and plasma fentanyl concentration was analyzed. A stable plasma fentanyl level was observed, and good pain control was achieved in
each patient using the three-cycle fentanyl patch system. A stable plasma fentanyl level was maintained the day before the conventional patch
replacement day.
Discussion: The three-cycle fentanyl patch system provided a stable plasma fentanyl concentration and excellent pain relief and should be
considered for pain control in cancer patients.
Copyright  2011, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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Fentanyl, a potent m-selective opioid receptor agonist, is
effective for the management of severe cancer pain. In patients
with intolerable pain, transfer to a transdermal fentanyl patch
offers an efficient and safe long-term analgesic option [1]. The
transdermal fentanyl patch was launched in Japan in March
2002 and has enabled opioid rotation. Fentanyl has been
incorporated into a transdermal therapeutic system containing
a rate-limiting membrane that provides constant release of the* Corresponding author. Department of Obstetrics and Gynecology, Kansai
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doi:10.1016/j.tjog.2011.01.006opioid from a reservoir. Plasma fentanyl concentrations are
barely detectable for about 2 hours after patch placement [2].
Eight to 12 hours after patch placement, plasma fentanyl
concentration is approximately equal to that achieved with an
equivalent intravenous dose of fentanyl [3]; therefore, it is rec-
ommended that the patches should be changed every 72 hours.
However, on the third day, before patch replacement, pain
control deteriorates because of decreased fentanyl release from
the patch. It was reported that patients complained of severe pain
on the replacement day in about one quarter of cases [4].
To maintain constant plasma level of fentanyl, we have
established a three-cycle fentanyl patch system. Three patches
were provided and were applied singly over 3 consecutive days
at 24-hour intervals, and replaced every 72 hours. One-third ofcs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
Fig. 1. Fentanyl patch application. (A) Conventional usage as recommended by the manufacturer. The fentanyl patch is designed to release fentanyl at a constant
rate for up to 72 hr. Application is recommended for every 72 hr. (B) Three-cycle fentanyl patch system. Three patches were provided, applied singly over 3
consecutive days at 24-hr intervals, and replaced every 72 hr. One-third of the patches was replaced every day to maintain a plasma level of fentanyl.
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serum level of fentanyl (Fig. 1). We have reported that this
system markedly improved cancer pain control [5].
In this study, we investigated plasma fentanyl levels in gyne-
cologic cancer patients using the three-cycle fentanyl patch
system. Stable plasma fentanyl concentration was shown
throughout the three-cycle fentanyl system application. Stable
control of the plasma fentanyl level was observed on the third day
corresponding to the day before patch replacement in conven-
tional usage. The three-cycle fentanyl patch system provided
a stable plasma fentanyl level and excellent pain control.Patients and treatmentBetween May 2007 and May 2008, five patients with
cancer-related pain who were hospitalized in Kansai Medical
University Hospital were treated using the three-cycle fentanyl
patch system. Three patches were provided and were applied
singly over 3 consecutive days at 24-hour intervals, and
replaced every 72 hours. One-third of the patches was therefore
replaced every day tomaintain a stable plasma level of fentanyl
(Fig. 1). Three of the five patients were used for plasma fen-
tanyl level analysis, and 15 plasma samples were analyzed. All
patients were fully informed about the procedure and the
purpose of this experiment, and gave written consent. All
protocols were approved by the local Human Investigation
Committee.Blood collectionBlood samples were collected three times every consecutive
3 days 2 hours before fentanyl patch replacement: Day I
corresponds to the conventional fentanyl patch replacement day,
Day II is the day after Day I, and Day III is the day after Day II,
corresponding to the day before fentanyl patch replacement inconventional usage. Blood samples were collected in heparin-
ized glass tubes. Blood samples were centrifuged (2,000g for 10
minutes) and then the plasma was transferred to polypropylene
tubes and stored at 80C until analysis.
Plasma fentanyl concentration analysisTo 200 mL plasma, 50 mL of methanol, 50 mL of the internal
standard solution (50 ng/mL methanol), 0.3 mL of water, and
1mLof 0.1mol/L sodiumhydroxidewere added and vortexed. A
3.5 mL mixture of heptan and isoamylalcohol (95:5,v/v) was
added and the samples were shaken for 10 minutes. The organic
phase of sampleswas extracted followed by centrifugation. Then,
4 mL of 0.05 mol/L sulfuric acid was added, the samples were
shaken and centrifuged, and then the organic phase was carried
out. Then, 0.15 mL of 28% ammonium hydroxide and a 2.5 mL
mixture of heptan and isoamylalcohol (95:5,v/v) were added to
the liquid phase and the sampleswere shaken for 10minutes. The
organic phase of samples was extracted, followed by centrifu-
gation, and evaporated at 50C with a nitrogen evaporator. The
residue was reconstituted in 50 mL of methanol and 2 mL was
injected into theGasChromatograph/Mass Spectrometer system.StatisticsStatistical analysis was performed using Stat View software
(SAS Institute Japan Ltd, Tokyo, Japan). The Friedman test was
used to compare the dispersion of plasma fentanyl concentration
on 3 consecutive days in the three-cycle fentanyl patch system.
The p values below 0.05 were considered to indicate statistical
significance.
Case Reports
Five patients were treated with the three-cycle fentanyl
patch system in this study. This system brought an effective
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them, enough blood samples were not obtained for plasma
fentanyl concentration analysis. We presented three cases and
stable plasma fentanyl concentration was shown throughout
the three-cycle fentanyl system application.Case 1A 56-year-old woman with stage IV ovarian clear cell
carcinoma diagnosed by an exploratory laparotomy with
intraperitoneal chemotherapy (CDDP was medicated intra-
peritoneally) was given 6 cycles of chemotherapy (paclitaxel
and carboplatin). Twelve cycles of weekly paclitaxel chemo-
therapy followed; however, a few months later she showed
symptoms of peritonitis carcinomatosa because of recurrent
tumor. She suffered severe pain and a fentanyl patch treatment
was started. The fentanyl patch treatment relieved her pain
with a dose up to 125 mcg/hr, and her visual analog scale
(VAS) pain score decreased from 5 to 1 following its appli-
cation, however, she complained of severe pain on the patch
replacement day. Therefore, a three-cycle fentanyl patch
system was started, and brought an effective pain relief andFig. 2. Three-cycle fentanyl patch system of Case 1. (A) VAS pain score deteriora
three-cycle fentanyl patch system provided an excellent pain relief and VAS pain s
fentanyl level was analyzed on 3 consecutive days. VAS ¼ visual analog scale.kept stable VAS pain score (Fig. 2A). Fentanyl 125 mcg/hr
brought about effective pain relief without nausea; 25 mcg/hr
patch was applied on the first day, 50 mcg/hr patch the next
day, and 50 mcg/hr patch on the third day (Fig. 2B). In this
figure, Day I was the day corresponding to the patch
replacement day in conventional usage. On Day II, one of the
fentanyl patches was replaced during the three-cycle fentanyl
patch system application; however, it was not replaced in
conventional usage. Day III was the patch replacement day in
the three-cycle fentanyl patch system and before patch
replacement in conventional usage. The plasma concentration
of fentanyl was analyzed and revealed a stable level
throughout the three-cycle fentanyl patch system application
(Case 1 in Fig. 3). The patient was mentally alert, and could
eat (VAS score remained 2) during her final 5 months with
the high-dose three-cycle fentanyl patch system.Case 2A 45-year-old woman diagnosed with uterine cervical cancer
(clinical stage IIIb, squamous cell carcinoma) was treated with
primary radiation therapy (total 65Gy) followed by four cycles ofted on the third day before patch replacement in the conventional usage. The
core was stabilized. (B) A 125 mcg/hr fentanyl brought pain relief and plasma
Fig. 4. Three-cycle fentanyl patch system of Case 2. (A) A 75 mcg/hr fentanyl brou
(B) A 125 mcg/hr fentanyl brought pain relief and plasma fentanyl level was analy
plasma fentanyl level was analyzed on 3 consecutive days.
Fig. 3. Plasma fentanyl level during application of the three-cycle fentanyl
patch system. The plasma fentanyl concentration of three cases was analyzed.
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Several months later, recurrent tumor invaded her ureter and
rectum, causing hydronephrosis and renal failure. A neph-
rostomy was established and a three-cycle fentanyl patch system
was applied to control her severe pain because nonsteroidal anti-
inflammatory drugs were unsuccessful. Her VAS score decreased
from 5 to 1 following the three-cycle fentanyl patch system
application. Plasma concentration of fentanyl was studied
at 75 mcg/hr fentanyl dose (Case 2-A in Fig. 3); one of the
25mcg/hr patches was replaced every day (Fig. 4A). Twomonths
later, her VAS score increased to 5 again and the dose of fentanyl
was increased to 125 mcg/hr (Fig. 4B), bringing good pain relief
(VAS score 1), and the plasma concentration of fentanyl was
studied (Case 2-B in Fig. 3). The dose of fentanyl was finally
increased to 150 mcg/hr with good pain control (Fig. 4C) and
plasma concentration of fentanyl was stable (Case 2-C in Fig. 3).
She was mentally alert, and could eat during her final 5 months
with the high-dose three-cycle fentanyl patch system.ght pain relief and plasma fentanyl level was analyzed on 3 consecutive days.
zed on 3 consecutive days. (C) A 150 mcg/hr fentanyl brought pain relief and
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endometrial adenocarcinoma of ovary diagnosed by total
hysterectomy, bilateral salpingo-oophorectomy, and partial
omentectomy. Thirty cycles of chemotherapy (paclitaxel and
carboplatin) were given in the following 6 years; however, she
showed symptoms of peritonitis carcinomatosa because of
recurrent tumor and suffered severe pain, and a three-cycle
fentanyl patch system was started. Fentanyl 75 mcg/hr
brought about effective pain relief without nausea, and her
VAS score decreased from 4 to 1 following this system
application (Fig. 5). The plasma concentration of fentanyl was
studied and was stable (Case 3 in Fig. 3). The pain was
relieved (VAS score remained 2) and she was mentally alert,
and could eat with the high-dose three-cycle fentanyl patch
system.
Discussion
The transdermal patch was designed to release fentanyl at
a constant rate for up to 72 hours. The amount of drug released
is proportional to the surface area of the patch, and four
different sizes are currently available with release rates of 25,
50, 75 and 100 mcg/hr. Fentanyl is a synthetic opioid with
short-acting analgesic activity. The fentanyl patch is very
useful for cancer pain control, however, pain control deterio-
rates because of decreased fentanyl release from the patch on
the third day before patch replacement. It was reported that
patients complained of severe pain on the replacement day in
about one quarter of cases [4]. This tendency was more
significant as the fentanyl dose increased. It was reported that
plasma fentanyl levels of patches depend on the dose, and
a positive correlation between plasma fentanyl concentrations
and the fentanyl patch dose was confirmed [5e9]. Strong pain
requires a dose of fentanyl. The decrease of fentanyl is
augmented on patch replacement day as the fentanyl dosage
increases and could cause more severe pain before patch
replacement in conventional usage. To obtain a constant
plasma level of fentanyl, we have established a three-cycle
fentanyl patch system; three patches were provided and
applied singly over 3 consecutive days at 24-hour intervals,
and replaced every 72 hours. One of the patches was therefore
replaced every day to obtain stable plasma levels of fentanyl.Fig. 5. Three-cycle fentanyl patch system of Case 3. A 75 mcg/hr fentanyl brougWe have reported three cases in which this system markedly
improved the control of cancer pain [5]. In this report, the
fentanyl plasma level during this system was studied and
a stable plasma fentanyl concentration was shown on Day III
corresponding to before patch replacement (Fig. 3). We
observed no significant difference in fentanyl plasma levels
between Day I, II, and III in five sets of analysis during the
three-cycle fentanyl patch system application (Friedman test,
p ¼ 0.78). This study confirmed that stable plasma fentanyl
concentration was maintained on the third day, corresponding
to before conventional patch replacement.
The fentanyl patch was reported to have fewer adverse
events than oral morphine treatment [6e10]. The most
frequently mentioned adverse events were reportedly nausea,
vomiting, and constipation. Clinical data show that con-
stipation occurs less frequently with transdermal fentanyl than
with oral morphine therapy [9,10]. One reason for this may be
the difference between the concentration required to achieve
analgesia and the concentration required to elicit a reduction in
intestinal activity. In addition, it was reported that fentanyl had
a high affinity mu1 site of opioid receptors, and the affinity of
fentanyl for mu2 receptors was lower than oral morphine [11].
The mu2 receptors mediate respiratory depression, physical
dependence, and inhibition of gastrointestinal motility.
Respiratory depression is the most serious adverse event
related to opioids. In this study, we noticed no respiratory
depression. This shows that fentanyl patches can be used
safely even in an opioid-naive setting in patients with no
history of CO2 retention. This finding is consistent with
previous studies [12].
Fentanyl patches should only be used in patients who are
already receiving opioid therapy according to Japanese
medical insurance and medication guide; therefore, we had to
use other opioids (excluded fentanyl patches) before the first
application of the fentanyl patch. The rise of the fentanyl
plasma level at the first patch application is gradual, and
patients cannot absorb excess opioid doses. [4e8] It is more
useful to apply fentanyl patches as the first opioid and this
could achieve excellent pain control with the initial fentanyl
application. We think that fentanyl patches could be used for
the initial opioid application when used in nonsteroidal anti-
inflammatory drug-tolerant patients.
Different from gastric cancer, gynecologic cancer patients
could eat and drink until the terminal stage in many cases. Theht pain relief and plasma fentanyl level was analyzed on 3 consecutive days.
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patients’ behavior. During application of the three-cycle fen-
tanyl patch system, many patients could eat, drink, and stay
overnight at home until the final stage. All patients described
the convenience of patch use as excellent. The administration
method of this system is extremely easy compared with
a continuous drip, and home recuperation could be possible
because patients could replace the patches at home after
training. This system can provide stable pain control and
allows freedom from injections, thereby enhancing the
patient’s quality of life. The three-cycle fentanyl patch system
is effective and safe for the management of cancer-related pain
and should be considered for pain relief in cancer patients.References
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